Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen

NANJING, China, April 29 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE:SCR - News), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen") has received disciplinary notice from China's State Food and Drug Administration ("SFDA") regarding its production of substandard quality human use rabies vaccine.